Glaucoma Awareness

The study, conducted in 2022, highlights significant variations in glaucoma prevalence across different demographic groups, states, and counties.

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.

A recent clinical study demonstrates that low intracranial pressure correlates with impaired patient visibility, especially in the nasal zone.

New educational campaign aims to educate individuals at risk for glaucoma and raise funding for glaucoma research.

Researchers found through DNA sequencing and confirmed in further testing that a genetic mutation in the THBS1 gene led to the development of severe childhood glaucoma. The discovery may improve disease screening and personalize treatments.

According to investigators, retinal aging caused by stress produces symptoms similar to those resulting from natural aging.

According to investigators, findings may underscore the need for sleep therapy in patients at risk for glaucoma, and frequent eye checkups for patients who are poor sleepers.

According to the Glaucoma Research Foundation, the collaborative research program will explore some of the common characteristics of glaucoma, Alzheimer’s.

Nanoscope Technologies LLC announced this week it has received Direct Phase II SBIR grant from National Institutes of Health for developing an innovative approach to autonomously regulate pressure for treatment of Glaucoma in a gene-agnostic manner.

In a poster presented at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Yu-Yen Chen, MD, PhD, noted that patients diagnosed with normal-tension glaucoma (NTG) have a significantly higher risk of developing Alzheimer’s disease compared with those without NTG.

Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and adverse effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.

A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.

Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.

According to researchers, findings could lead to new screening protocols to catch glaucoma early and preserve vision.

The research points to the importance of isolating offending organism.

According to Sarah Van Tassel, MD, physicians may need to recognize issues and treat patients more holistically.

According to Johns Hopkins Medicine researchers, as little as $65 per year appears to influence practitioners, making them up to twice as likely to prescribe the companies’ brand name eyedrops for glaucoma instead of cheaper generic versions.

Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.

The lower energy applications and slower sweep speeds offer marked IOP reductions in patients.

A team of investigators from the Yong Loo Lin School of Medicine at the National University of Singapore has found that there is a bidirectional association between chronic kidney disease and glaucoma.

The research is the result of a national collaboration led by investigators from the Centre for Eye Research Australia at the University of Melbourne and University of Tasmania and the Garvan Institute of Medical Research.

According to the company, no safety concerns with corneal endothelial health reported across all 3 trials, and the device delivered consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe.

Two grants will be available, each offering $150,000 to scientists focusing on glaucoma research who have already received their first independent federal National Institutes of Health (NIH) grant and are collecting new and novel data to apply for a second R01.

A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some of the previous challenges associated with cannabis use and may present a new potential therapeutic intervention in the treatment of glaucoma.

In advance of World Glaucoma Week March 6-12, a study of 3826 patients with glaucoma has found significantly higher odds of self-reported difficulty affording medication observed among non-Hispanic African American and Hispanic individuals compared with non-Hispanic White individuals.

The company’s new technology, which targets the eye’s conventional outflow pathway, is expected to have full commercial availability on April 1.

A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.